晚间公告丨4月14日这些公告有看头

Group 1 - *ST Dongfang has triggered a mandatory delisting situation due to its stock price being below RMB 1 for 20 consecutive trading days, leading to a suspension of trading starting April 15, 2025 [3] - Jifeng Technology's controlling shareholder is planning a change of control, resulting in the stock being suspended since April 11, 2025, with an expected continuation of suspension for no more than 3 trading days [4] - Wantai Biological has initiated a Phase III clinical trial for its nine-valent HPV vaccine in males, having received approval from the National Medical Products Administration [5] Group 2 - Youyan New Materials expects a net profit of RMB 60 million to 75 million for Q1 2025, representing a year-on-year increase of 13076% to 16370% [7] - Jinrui Mining anticipates a net profit of approximately RMB 15.28 million for Q1 2025, reflecting a year-on-year increase of 617.40% [8] - Guoli Co., Ltd. projects a net profit of RMB 11 million to 13 million for Q1 2025, with a year-on-year growth of 164.38% to 212.45% driven by the booming electric vehicle market [9] - Shenzhen Huaqiang expects a net profit of RMB 9.644 million to 11.481 million for Q1 2025, indicating a year-on-year increase of 68% to 100% [10] - Changshu Bank reported a net profit of RMB 1.084 billion for Q1 2025, up 13.87% year-on-year [12] - Junda Co. reported a net loss of RMB 106 million for Q1 2025, with a revenue decline of 49.52% year-on-year [13] - Shandong Gold anticipates a net profit of RMB 950 million to 1.13 billion for Q1 2025, representing a year-on-year increase of 35.74% to 61.45% [14] - Wuzhou Special Paper reported a net profit of RMB 64.68 million for Q1 2025, down 51.56% year-on-year [15] - Shuangxiang Co. reported a net profit of RMB 472 million for 2024, up 754.84% year-on-year [16] - Zhongmi Holdings reported a net profit of RMB 392 million for 2024, up 13.21% year-on-year [17] - Xijun Airlines reported a 3.37% year-on-year increase in passenger turnover for March 2025 [18] - Xinbang Pharmaceutical reported a net profit of RMB 101 million for 2024, down 64.70% year-on-year [19] Group 3 - Kailong Co.'s controlling shareholder plans to increase its stake by investing between RMB 90 million and 180 million over the next six months [21] - Industrial Fulian intends to repurchase shares worth between RMB 500 million and 1 billion for capital reduction [23] - Guodian Nanrui plans to repurchase shares worth between RMB 500 million and 1 billion for future employee incentive plans [24] - Zhejiang Pharmaceutical plans to repurchase shares worth between RMB 100 million and 200 million for employee stock ownership plans [25] - Lingang Co.'s chairman proposed a share repurchase of between RMB 50 million and 100 million for incentive purposes [26] - Fujia Co. plans to repurchase shares worth between RMB 15 million and 30 million for employee stock ownership plans [27] Group 4 - Chengdi Xiangjiang's subsidiary won a bid for a project with China Mobile in Anhui, valued at RMB 24.33 billion [29]